June 11, 2020 / 5:28 AM / 2 months ago

Lonza partners with Anthos Therapeutics for thrombosis treatment

FILE PHOTO: The logo of Swiss pharmaceutical group Lonza is seen at its headquarters in Basel, Switzerland March 26, 2019. REUTERS/Arnd Wiegmann

ZURICH (Reuters) - Lonza has signed a partnership agreement with Anthos Therapeutics, the Swiss company said on Thursday, to develop and manufacture an antibody treatment for blood clots.

Anthos, a biotech created by Blackstone Life Sciences and Novartis, will get access to Lonza’s drug substance, drug product and labeling/packaging services to speed the launch of Abelacimab, a treatment for patients at risk of thrombosis.

Reporting by John Revill; editing by Thomas Seythal

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below